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Abstract
Purpose—To describe which providers provide breast cancer survivorship care.
Patients and Methods—We conducted a longitudinal survey of non-metastatic breast cancer
patients identified by the SEER registries of Los Angeles and Detroit. Multinomial logistic
regression examined the adjusted odds of surgeon compared with a medical oncologist follow up
or primary care provider compared with medical oncologist follow up, adjusting for age, race/
ethnicity, insurance, tumor stage, receipt of chemotherapy, endocrine therapy use, and visit to a
medical oncologist at the time of diagnosis. Results were weighted to account for sample selection
and non-response.
Results—844 women had invasive disease and received chemotherapy or endocrine therapy.
65.2% reported medical oncologists as their main care provider at four years, followed by PCP/
other physicians (24.3%) and surgeons (10.5%). Black women were more likely to receive their
follow-up care from surgeons (OR 2.47, 95% CI 1.16–5.27) or PCP/other physicians (OR 2.62,
95% CI 1.47–4.65) than medical oncologists. Latinas were more likely to report PCP/other
physician follow up than medical oncologists (OR 2.33, 95% CI 1.15–4.73). Compared with
privately-insured women, Medicaid recipients were more likely to report PCP/other physician
follow up (OR 2.52, 95% CI 1.24–5.15). Women taking endocrine therapy four years after
diagnosis were less likely to report surgeons or PCP/other physicians as their primary provider of
breast cancer follow up care.
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Conclusions—Different survivorship care patterns based on race/ethnicity and insurance status.
Interventions are needed to inform patients and providers on the recommended sources of breast
cancer follow up.
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INTRODUCTION
The current care delivery model for cancer survivorship is unsustainable for three key
reasons [1]. First, the number of cancer survivors has increased markedly and will continue
to do so due to early detection and treatment advances [2]. Second, the surge in the cancer
survivor population coincides with projected shortages of medical oncologists [3,4] and
primary care physicians [5,6]. Third, follow-up care remains inadequate or fragmented for
many cancer survivors [7].
In the case of breast cancer, it is unclear how women should receive follow-up care after
treatment. Breast cancer survivors require follow up to assess for recurrence and late effects
of therapy. In particular, women who receive chemotherapy and/or endocrine therapy
experience an array of effects, including peripheral neuropathy, osteoporosis, or organ
toxicity [8–11]. Breast cancer survivors receive follow-up care in a number of settings. Yet
no current guidelines identify the optimal providers of breast cancer care and the optimal
time points for transition. Medical oncologists and primary care providers differ in their
perspectives and preferences for breast cancer follow-up care [12,13]. Most survivors
receive care from either medical oncologists or primary care physicians; fewer patients
receive follow up from surgical oncologists or other providers [14]. There are divergent
preferences from patients [15] and oncologists [16] on the ideal source for breast cancer
survivorship care.
A better understanding of the types of providers breast cancer patients see in the
survivorship period can inform policies targeted to improve the quality and efficiency of
survivorship care. Clinicians and researchers must comprehend the survivorship experience
from distinct racial/ethnic groups given the differential mortality rates observed [2] in the
absence of disparate chemotherapy treatment [17]. The study objective was to examine
patterns of follow-up care by patient, disease, and treatment factors in a large, diverse,
population-based sample of breast cancer patients treated with endocrine or chemotherapy.
The results fill a knowledge gap of the experience of diverse women seeking long-term
breast cancer follow up.
PATIENTS AND METHODS
Research Design
This prospective longitudinal study used rapid case ascertainment methods in partnership
with two cancer registries that participate in the Surveillance, Epidemiology and End-
Results (SEER) program. The data collection protocol has been summarized previously [18].
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Eligible women from Los Angeles County and Metropolitan Detroit were surveyed at two
time points. Latinas in Los Angeles and black women in both Detroit and Los Angeles were
oversampled. Baseline surveys were mailed to participants between June 2005 and February
2007, which was around 9 months after the initial breast cancer diagnosis. Follow-up
surveys were mailed around 4 years after initial diagnosis.
After human subjects’ approval at the University of Michigan and parallel approvals in
California and Detroit, cases were reported monthly to SEER registries. We notified
physicians by mail of our intent to survey their patients. Next, we mailed patients a packet
with a cover letter, a printed survey copy, a statement of study risks and benefits, and a $10
cash gift. To encourage high response rates, we modified the methods specified by Dillman
[19]. These included a reminder letter, followed by a second survey to non-respondents,
followed by a follow-up telephone call.
Study Participants
Women were eligible to participate if they were between 20 and 79 years of age, diagnosed
with ductal carcinoma in situ or invasive non-metastatic breast cancer (Stages I–III) between
June 2005 and February 2007, and reported to the Los Angeles County or Metropolitan
Detroit SEER registries. Surveys were administered in both English and Spanish. Asian
women were not included due to a second concurrent active study.
Variables
The outcome variable was patient report of the primary provider breast cancer follow up
approximately four years after initial diagnosis; this was obtained from the follow-up
survey. Women were asked to identify their main provider of breast cancer follow-up care:
medical oncologist, surgeon, or primary care physician (PCP) physician. Women were also
given the opportunity to name another type of physician. Due to the small number of write-
in options, these physicians were lumped into the PCP category.
SEER registries provided age (in years) and cancer stage at diagnosis (I, II, or III) at the
baseline survey period. At baseline, patients provided: race/ethnicity (white, black, Latina),
receipt of systemic adjuvant chemotherapy (yes/no), insurance coverage (Medicaid,
Medicare, private/other insurance, not insured), education (some high school, completed
high school, attended or completed college), and whether they consulted a medical
oncologist before their initial breast cancer operation. The follow-up patient survey asked
women about their use of endocrine therapy for breast cancer; response choices were never
taken, took in the past but no longer, and current use at the time of the survey.
Analyses
First, we measured the proportion of women who reported that medical oncologists,
surgeons, or primary care/other physicians were their primary provider of breast cancer care
approximately four years after diagnosis. We then examined differences in the proportion of
women who saw medical oncologists versus surgeons or PCPs/other provider types by the
covariates listed above. We used multinomial regression to determine the adjusted odds of
surgeon versus medical oncologist follow up as well as the adjusted odds of PCP/other
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provider versus medical oncologist follow up. All results were weighted to account for
differential probabilities of sample demographics and non-response and were conducted in
SAS version 10.1.
RESULTS
Of the 1,536 women who completed both baseline and follow-up surveys, 366 were
excluded from this analysis due to non-invasive disease and 86 were excluded due to
recurrence by the time of the follow-up survey. Because our analysis was focused
specifically on women who received systemic therapy, we excluded the 99 women in the
sample who did not report at baseline receipt of either chemotherapy or endocrine therapy.
141 women were also excluded because of missing survey data. The final analytic sample
consisted of 844 women.
Sample characteristics are presented in Table 1. The sample’s race/ethnicity was white
(43.6%) followed by Latina (40.7%) and black (15.7%). The mean (SD) age of respondents
was 56.5(11.4) years. The majority of respondents (61%) reported private insurance
coverage, 19.5% reported Medicare coverage, 11.6% received Medicaid, and 8.3% reported
no coverage. Most of the sample (69%) received systemic chemotherapy. Four years after
diagnosis, 45.3% reported current endocrine therapy use and an additional 28.6% reported
previous use. Over 90% of respondents reported a consultation with a medical oncologist
before their initial breast cancer operation. Of the 844 women with requisite data for
analyses, 65.2% of women reported medical oncologists as the main provider of
survivorship care at 4 years, followed by PCP/other physicians (24.3%) and surgeons
(10.5%).
Receipt of Follow Up by Provider Type
The multinomial logistic regression model examines two comparative outcomes: receipt of
follow-up care by surgeon versus medical oncologists (n=706) and PCP/other versus
medical oncologists (n=784) (Table 2). Relative to white women, black women were
significantly more likely report follow up with a surgeon (OR: 2.47 95% CI: 1.16–5.27) or
PCP/other (OR: 2.62 95% CI:1.47–4.65) versus a medical oncologist. Latinas were
significantly more likely than white women to be seen by a PCP/other rather than a medical
oncologist (OR: 2.33 95% CI: 1.15–4.73). Relative to women with private insurance
coverage, those with Medicaid coverage were significantly more likely to be seen by a PCP/
other than by a medical oncologist for follow-up care (OR: 2.52 95% CI:1.24–5.15). Current
endocrine therapy use was associated with medical oncologist follow up: compared with
women who had never taken endocrine therapy, current endocrine therapy users were less
likely to see a surgeon (OR: 0.35 95% CI: 0.14–0.86) or a PCP/other (OR: 0.33 95% CI:
0.17–0.64) than a medical oncologist.
The variables in the multinomial logistic regression model were used to calculate the
adjusted proportion of women who reported each type of provider for their follow-up breast
cancer care at four years (Figure 1). While the overall majority of women reported medical
oncologist follow-up, differences were observed by race/ethnicity: 83% of white women,
77% of Latinas, and 65% of black women reported medical oncologist follow-up (p<.001).
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Whites and Latinas both reported similar rates of surgeon follow-up (6%), yet 12% of black
women saw surgeons. Black women saw PCP/other physicians more often (23%) than
Latinas (17%) or white women (11%).
DISCUSSION
In this diverse sample of women treated with systemic chemotherapy or endocrine therapy
for invasive breast cancer, most women reported follow-up care by medical oncologists
versus surgeons or PCPs/other provider types. However, significant differences in follow up
care were observed by race/ethnicity and insurance status. In particular, we found black
women were significantly less likely than white women to receive breast cancer follow-up
care from a medical oncologist versus any other provider type, regardless of receipt of
chemotherapy or endocrine therapy. Latinas, too, were less likely to see a medical
oncologist versus any other provider type at follow-up, relative to whites. Different patterns
of survivorship care emerge for women based on race/ethnicity and insurance status.
Nationally, surgeons provide a very small amount of breast cancer survivorship care relative
to medical oncologists and primary care providers [14]. For women who receive systemic
and/or endocrine therapy and who do not experience recurrence, it is unclear what aspects of
care surgeons would attend to four years after diagnosis. Yet black women in our sample
reported seeing surgeons at twice the rate of Latinas or white women. These findings point
to the need to better understand how breast cancer follow up care is delivered across diverse
settings.
Endocrine therapy after primary breast cancer treatment is recommended for at least five
years [20]. Recent clinical trials confirm significant survival advantages for tamoxifen
therapy extended to ten years [21,22]. Yet adherence to five years of therapy is low [23–27].
Despite impressive efficacy in reducing recurrence, endocrine therapy is associated with a
host of bothersome side effects including, among others, hot flashes, sexual side effects, and
arthralgias. Adverse effects often lead women to discontinue therapy [28–32]. Previously
reported data from the current study suggest that the subset of women eligible for endocrine
therapy were more likely to persist with using therapy when reporting medical oncologist
follow up [27]. It may be the case that women who persist on endocrine therapy follow up
with oncologists for side effect management. Additional studies are needed to understand
the processes employed by medical oncologists to support women on endocrine therapy, and
disseminate these processes to the range of providers who provide follow-up care in the
survivorship setting.
Study Limitations
First, we only asked patients to list their primary source of oncology follow-up care, which
precludes our ability to measure the presence of shared care models. Patients seen by a team
of providers are more likely to receive recommended care [33,34]. Consequently, a shared
care model has recently been proposed as a recommended survivorship care model by both
the American Cancer Society and American Society of Clinical Oncology for those patients
for whom it is appropriate [11].
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Surveys occurred at two time points: approximately nine months and four years after
diagnosis. Thus, we are not able to determine whether some patients switched their primary
follow-up provider between those time points. For example, women may have transitioned
from medical oncologist to primary care three years after treatment. We lack data on
possible reasons for a transition, which in some cases may have been appropriate [35].
Future studies to examine use of different providers in breast cancer survivorship care would
benefit from more detailed reasons why patients transition from medical oncologists to other
providers.
The primary source of study data derives from patient report. While recall bias is possible,
the period in which women were asked to recall specific events is narrow enough to suggest
reliable estimates. External data would validate these findings and inform future research
focused on care patterns of breast cancer survivors. These limitations are presented
alongside a large, diverse population-based sample with high response survey rates at two
time points.
Implications
In a population-based sample of diverse early stage breast cancer patients, we found
important differences in follow-up care by patient and treatment factors. Amidst a demand
surge for cancer care, a substantial number of breast cancer survivors who have not
experienced recurrence continue to see their medical oncologists for survivorship care four
years after initial diagnosis. These results suggest a possible mismatch of needs and
resources among breast cancer survivors and available providers. Differences in
survivorship care patterns by race/ethnicity require clarification. Specifically, the role of
surgical follow up for 12% of black women is unclear in the absence of disease recurrence.
From the perspective of clinical policy development, there is an urgent need for specialties
that treat women with breast cancer to reach consensus on transition plans that are
acceptable to both providers and patients. Doing so will increase the likelihood of an
efficient, patient-centered cancer care delivery system [1]. Care coordination in the
survivorship period can optimize outcomes for breast cancer patients, yet care transitions
from oncology to non-oncology practices is difficult for both patients and providers [36,37].
Intervention studies have failed to improve outcomes for patients who receive survivorship
care plans that are shared across providers [38].
It is important to emphasize the absence of empirical data to develop breast cancer
survivorship guidelines. Not all patients need to see a medical oncologist four years after
treatment [35]. Primary care providers have indicated their willingness to participate earlier
in cancer survivorship care [39]. Suggestions to improve their comfort include ready access
to oncology specialists, treatment summaries, and access to imaging. A dialogue among care
providers to breast cancer is needed to clarify transition points and care goals. Educational
interventions - targeted to patients and providers - are needed to guide decision making for
survivorship care. Our data suggest interventions targeted to specific groups based on race/
ethnicity and insurance status may prove useful in responsible resource allocation.
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Table 1
Sample Characteristics
PERSONAL FACTORS N Weighted %
Age
 Mean(SD) 56.5(11.4) -
Race:
 White 430 43.6
 Black 186 15.7
 Latina 228 40.7
Insurance Coverage:
 Private or other employer-based insurance 538 60.6
 Medicare 173 19.5
 Medicaid 77 11.6
 No insurance 56 8.3
Education:
 Less than high school 141 23.4
 High school graduate 159 17.8
 Some college or college graduate 544 58.8
DISEASE FACTORS
Stage:
 I 392 40.1
 II 341 43.5
 III 111 15.4
TREATMENT FACTORS
Received Systemic Chemotherapy:
 Yes 566 69.1
 No 278 30.9
Endocrine Therapy Use
 Never 207 26.1
 Past 262 28.6
 Current 375 45.3
Consulted with Medical Oncologist prior to Initial Surgery:
 No 778 8.1
 Yes 66 91.9
Percentages reported are weighted for sample demographics and survey non-response.
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Table 2
Adjusted multinomial regression model, odds of follow-up care with a surgeon compared with a medical
oncologist and odds of follow-up care with a PCP/other compared with medical oncologist
Surgeon vs. Medical Oncologist Follow Up
n=706
PCP/other vs. Medical Oncologist Follow Up
n=784
OR 95% CI OR 95% CI
Age (years) 0.99 0.96–1.03 1.02 0.99–1.05
Race
 White 1.00 1.00
 Black 2.47 1.16–5.27 2.62 1.47–4.65
 Latina 1.36 0.50–3.71 2.33 1.15–4.73
Insurance Coverage
 Private/other 1.00 1.00
 Medicare 2.47 0.88–6.96 1.28 0.64–2.56
 Medicaid 0.94 0.19–4.65 2.52 1.24–5.15
 No insurance 1.67 0.44–6.27 0.93 0.35–2.44
Education
 Less than high school 1.00 1.00
 High school graduate 0.98 0.33–2.92 0.79 0.39–1.62
 Some college or more 1.04 0.41–2.59 0.72 0.38–1.34
Stage
 I 1.00 1.00
 II 0.97 0.46–2.02 1.03 0.55–1.94
 III 0.56 0.20–1.62 0.83 0.34–2.05
Received Systemic Chemotherapy
Yes 1.00 1.00
No 1.58 0.61–4.10 1.14 0.53–2.43
Endocrine Therapy Use
 Never 1.00 1.00
 Past 0.54 0.21–1.36 0.67 0.35–1.26
 Current 0.35 0.14–0.86 0.33 0.17–0.64
PCP: Primary Care Physician
Model adjusted for baseline consultation with medical oncologist before breast cancer surgery and geographic location. Model weighted for sample
demographics and survey non-response.
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